Autologous Stem Cell Mobilization in the Age of Plerixafor

Micro-Abstract Plerixafor is a potent stem cell–mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization or after prior failure of chemotherapy plus G-CSF wa...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2016-07, Vol.16 (7), p.411-416
Main Authors: Cooper, Dennis L, Medoff, Erin, Patel, Natalie, Baker, Julie, Pratt, Kathryn, Foss, Francine, Seropian, Stuart E, Perreault, Sarah, Wu, Yanyun
Format: Article
Language:English
Subjects:
Adult
Aged
Antigens, CD34 - metabolism
Female
Graft Survival
Granulocyte Colony-Stimulating Factor - pharmacology
Growth factors
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Mobilization - methods
Hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic Stem Cells - drug effects
Hematopoietic Stem Cells - metabolism
Heterocyclic Compounds - pharmacology
Humans
Lymphoma - therapy
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - therapy
Plerixafor
Stem cell mobilization
Treatment Outcome
Workflow
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract Plerixafor is a potent stem cell–mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization or after prior failure of chemotherapy plus G-CSF was associated with successful mobilization in 97.5% of patients, with target collections achieved in 60% of lymphoma and 72% of myeloma patients.
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2016.04.007